TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)
Brief Summary: Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline, a prescription medicine also known as Chantix,®. Other patients will receive a placebo drug. A placebo is an inactive substance that contains no medicine. All patients will receive smoking cessation counseling provided by our tobacco treatment specialists. They hope that what the researchers learn from this study will help us improve our smoking cessation treatment program for breast cancer patients.


Options:
A: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
C: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)
Brief Summary: Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline, a prescription medicine also known as Chantix,®. Other patients will receive a placebo drug. A placebo is an inactive substance that contains no medicine. All patients will receive smoking cessation counseling provided by our tobacco treatment specialists. They hope that what the researchers learn from this study will help us improve our smoking cessation treatment program for breast cancer patients.


Options:
A: Intervention Type: DRUG; Name: sustained-release bupropion (Zyban(R)); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychodynamic Model Training (R) = PDM(R); Assigned to Arm(s): N/A
B: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)
Brief Summary: Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline, a prescription medicine also known as Chantix,®. Other patients will receive a placebo drug. A placebo is an inactive substance that contains no medicine. All patients will receive smoking cessation counseling provided by our tobacco treatment specialists. They hope that what the researchers learn from this study will help us improve our smoking cessation treatment program for breast cancer patients.


Options:
A: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis
Brief Summary: A pragmatic, multicentre, randomized double-blind controlled trial with an intention-to-treat analysis, of the use of preimplantation genetic screening (PGS) for aneuploidy by means of microarray comparative genomic hybridization (CGH) for the chromosomal analysis of the polar bodies (PB) of oocytes collected after ovarian stimulation for in vitro fertilization (IVF), and with the intention to assess the genetic competence of oocytes of advanced biological age, and the effect of this technique on reproductive outcome.


Options:
A: Arm Label: Control (no PGD); Type: N/A; Interventions: N/A | Arm Label: Case (PGD); Type: N/A; Interventions: N/A
B: Arm Label: Polar Body Biopsy; Type: EXPERIMENTAL; Interventions: Other: Polar Body Biopsy | Arm Label: No Polar Body Biopsy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Polar Body Biopsy; Assigned to Arm(s): Polar Body Biopsy
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Genetic: single embryo transfer without aneuploidy screening | Arm Label: B; Type: EXPERIMENTAL; Interventions: Genetic: single embryo transfer with aneuploidy screening | Intervention Type: GENETIC; Name: single embryo transfer without aneuploidy screening; Assigned to Arm(s): A | Intervention Type: GENETIC; Name: single embryo transfer with aneuploidy screening; Assigned to Arm(s): B
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Application of Citrate Dialysate in Chronic Haemodialysis
Brief Summary: Study investigating the safety and efficacy of the citrate dialysis solution compared to standard acetate dialysis solution. Use of citrate dialysis solution is not associated with a clinically relevant development of adverse events. It is hypothesized that citrate dialysate may provide a local anticoagulation effect in the dialyser improving removal of uremic toxins.


Options:
A: Arm Label: HD treated with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: post-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: pre-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: HD treated with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: post-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: pre-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Intervention Type: DEVICE; Name: Citrate dialysate (CiDi); Assigned to Arm(s): HD treated with citrate dialysate, post-dilution oHDF with citrate dialysate, pre-dilution oHDF with citrate dialysate | Intervention Type: DEVICE; Name: Standard dialysate (StDi); Assigned to Arm(s): HD treated with standard dialysate, post-dilution oHDF with standard dialysate, pre-dilution oHDF with standard dialysate
B: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Meditation Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: Meditation | Arm Label: Control Group (No Meditation Exposure); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Meditation; Assigned to Arm(s): Meditation Intervention Arm
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cholecalciferol as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
Brief Summary: This research is being done to study the effectiveness of vitamin D (cholecalciferol) to modify hepcidin levels in children with chronic kidney disease (CKD). Anemia is a common problem in children with CKD. Anemia is when the body does not have enough healthy red blood cells. Hepcidin is a protein in the blood which interferes with the body's production of red blood cells. This study will see if vitamin D lowers hepcidin levels in children and young adults with CKD. If so, it could be used as an additional treatment for anemia in these children, in addition to the current therapies already in use including iron supplements and erythropoietin. People between the ages of 1 and 21 with CKD may be considered for this study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
B: Arm Label: 400 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 4000 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 400 IU vitamin D, 4000 IU vitamin D
C: Arm Label: Devit-3 Oral Drop 400 IU; Type: OTHER; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 800 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 1000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Intervention Type: DRUG; Name: Devit-3 Oral Drop; Assigned to Arm(s): Devit-3 Oral Drop 1000 IU, Devit-3 Oral Drop 400 IU, Devit-3 Oral Drop 800 IU
D: Arm Label: Maternal and Neonatal Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Maternal and Neonatal Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Maternal and Neonatal Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Maternal and Neonatal Control Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen
Brief Summary: This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative colitis (UC).


Options:
A: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)
B: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo
C: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
D: Arm Label: Dersalazine; Type: EXPERIMENTAL; Interventions: Drug: Dersalazine sodium | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dersalazine sodium; Assigned to Arm(s): Dersalazine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen
Brief Summary: This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative colitis (UC).


Options:
A: Arm Label: Mesalamine (Asacol) Once-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Once-Daily | Arm Label: Mesalamine (Asacol) Twice-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Twice-Daily | Intervention Type: DRUG; Name: Mesalamine Once-Daily; Assigned to Arm(s): Mesalamine (Asacol) Once-Daily | Intervention Type: DRUG; Name: Mesalamine Twice-Daily; Assigned to Arm(s): Mesalamine (Asacol) Twice-Daily
B: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)
C: Arm Label: Increase mesalamine dose by 2.4g/day; Type: EXPERIMENTAL; Interventions: Drug: mesalamine | Arm Label: Maintain mesalmine dose; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): Increase mesalamine dose by 2.4g/day
D: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BPH-6: A UroLift® System Post Market Multi-Center Randomized Study
Brief Summary: The purpose of this study is to compare the UroLift System Treatment to Transurethral Resection of the Prostate (TURP) in improving a patient's overall quality of life, while evaluating healthcare expenditures associated with each therapy.


Options:
A: Arm Label: UroLift System; Type: ACTIVE_COMPARATOR; Interventions: Device: UroLift System | Arm Label: Transurethral Resection of the Prostate; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transurethral Resection of the Prostate | Intervention Type: DEVICE; Name: UroLift System; Assigned to Arm(s): UroLift System | Intervention Type: PROCEDURE; Name: Transurethral Resection of the Prostate; Assigned to Arm(s): Transurethral Resection of the Prostate
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: Rezum System | Arm Label: Control; Type: OTHER; Interventions: Procedure: Rigid Cystoscopy | Intervention Type: DEVICE; Name: Rezum System; Assigned to Arm(s): Treatment | Intervention Type: PROCEDURE; Name: Rigid Cystoscopy; Assigned to Arm(s): Control
C: Arm Label: UroLift System; Type: ACTIVE_COMPARATOR; Interventions: Device: UroLift System | Arm Label: Cystoscopy; Type: SHAM_COMPARATOR; Interventions: Other: Cystoscopy | Arm Label: Crossover; Type: ACTIVE_COMPARATOR; Interventions: Device: Crossover | Intervention Type: DEVICE; Name: UroLift System; Assigned to Arm(s): UroLift System | Intervention Type: OTHER; Name: Cystoscopy; Assigned to Arm(s): Cystoscopy | Intervention Type: DEVICE; Name: Crossover; Assigned to Arm(s): Crossover
D: Arm Label: Participants Aged 40 Years or Over; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of QUTENZA® in Subjects With Painful Diabetic Peripheral Neuropathy
Brief Summary: The purpose of the study is to assess efficacy and safety of a single treatment of Capsaicin 8% transdermal delivery system in reducing pain from damaged nerves (neuropathic pain) caused by diabetes.


Options:
A: Intervention Type: DRUG; Name: NGX-4010; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
C: Arm Label: Capsaicin 8%; Type: EXPERIMENTAL; Interventions: Drug: Capsaicin 8% | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Capsaicin 8%; Assigned to Arm(s): Capsaicin 8% | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: NGX-4010, 60 minutes; Type: EXPERIMENTAL; Interventions: Drug: NGX-4010, 8% capsaicin patch | Arm Label: NGX-4010, 30 minutes; Type: EXPERIMENTAL; Interventions: Drug: NGX-4010, 8% capsaicin patch | Arm Label: 0.04% conc. capsaicin patch, 60 min.; Type: OTHER; Interventions: Drug: 0.04% capsaicin patch | Arm Label: 0.04% conc. capsaicin patch, 30 min.; Type: OTHER; Interventions: Drug: 0.04% capsaicin patch | Intervention Type: DRUG; Name: NGX-4010, 8% capsaicin patch; Assigned to Arm(s): NGX-4010, 60 minutes | Intervention Type: DRUG; Name: 0.04% capsaicin patch; Assigned to Arm(s): 0.04% conc. capsaicin patch, 60 min. | Intervention Type: DRUG; Name: NGX-4010, 8% capsaicin patch; Assigned to Arm(s): NGX-4010, 30 minutes | Intervention Type: DRUG; Name: 0.04% capsaicin patch; Assigned to Arm(s): 0.04% conc. capsaicin patch, 30 min.

Answer: C